← Markets
FDA moves BPC-157 to Category 1 by…?

FDA moves BPC-157 to Category 1 by…?

Resolves Jan 1, 2027·$50 24h vol·culture
$3.5k total volume·Open for 65 days

December 31, 2026

50%-13.5%
OutcomeYesNo
December 31, 2026
August 31, 2026

Order Book

December 31, 2026

PriceSharesTotal
99.0¢49$48
98.0¢46$45
97.0¢16$16
95.0¢10$10
94.0¢8$7
89.0¢50$45
88.0¢30$26
87.0¢40$35
13.0¢last trade
74.0¢ spread
13.0¢23$3
11.0¢40$4
10.0¢31$3
7.0¢13$1
6.0¢80$5
5.0¢300$15
4.0¢750$30
3.0¢1.2k$36
$97 bids$232 asks

Resolution Criteria

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

December 31, 2026

50%